Abstract
The continuously aging population in the western nations has to be regarded as a new challenge that requires professional strategies concerning medical oncologic treatments of the elderly. The incidence of malignant lymphoma is increasing beyond the age of 65. The presented case report describes the innovative therapy protocol that combines the monoclonal antibody rituximab with the antineoplastic agent, bendamustine, in the adjuvant treatment of an aggressive non-hodgkin lymphoma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
